BR112013018642A2 - vacinas e composições contra streptococcus pneumoniae - Google Patents

vacinas e composições contra streptococcus pneumoniae

Info

Publication number
BR112013018642A2
BR112013018642A2 BR112013018642-9A BR112013018642A BR112013018642A2 BR 112013018642 A2 BR112013018642 A2 BR 112013018642A2 BR 112013018642 A BR112013018642 A BR 112013018642A BR 112013018642 A2 BR112013018642 A2 BR 112013018642A2
Authority
BR
Brazil
Prior art keywords
streptococcus pneumoniae
compositions
pneumoniae vaccines
vaccines
present
Prior art date
Application number
BR112013018642-9A
Other languages
English (en)
Inventor
Gierahn Todd
Malley Richard
Original Assignee
Genocea Biosciences Inc.
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc., Children's Medical Center Corporation filed Critical Genocea Biosciences Inc.
Publication of BR112013018642A2 publication Critical patent/BR112013018642A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

formulação de vacina contra streptococcus pneumoniae a presente invenção refere-se a streptococcus pneumoniae que é uma grande preocupação de saúde, em especial em 5 pacientes muito novos, idosos, ou imunocomprometidos. a presente divulgação provê, inter alia, certas vacinas e composições farmacêuticas altamente eficazes contra streptococcus pneumoniae. os antígenos podem ser usados de modo terapêutico ou profilático.
BR112013018642-9A 2011-01-20 2012-01-20 vacinas e composições contra streptococcus pneumoniae BR112013018642A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434818P 2011-01-20 2011-01-20
US61/434,818 2011-01-20
PCT/US2012/022128 WO2012100234A1 (en) 2011-01-20 2012-01-20 Vaccines and compositions against streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
BR112013018642A2 true BR112013018642A2 (pt) 2019-04-30

Family

ID=46516136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018642-9A BR112013018642A2 (pt) 2011-01-20 2012-01-20 vacinas e composições contra streptococcus pneumoniae

Country Status (14)

Country Link
US (2) US9393294B2 (pt)
EP (1) EP2665490B1 (pt)
JP (1) JP6126993B2 (pt)
KR (1) KR20140017554A (pt)
CN (2) CN105833260A (pt)
AU (2) AU2012207089B2 (pt)
BR (1) BR112013018642A2 (pt)
CA (1) CA2861313A1 (pt)
IL (1) IL227554A (pt)
MX (1) MX344120B (pt)
MY (1) MY163871A (pt)
RU (1) RU2623174C2 (pt)
SG (2) SG192060A1 (pt)
WO (2) WO2012100234A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008548A1 (en) * 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2011112906A2 (en) 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
EP2804627B1 (en) * 2012-01-20 2019-08-14 Genocea Biosciences Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014210031A1 (en) * 2013-06-25 2014-12-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Proteomic biomarkers of sepsis in elderly patients
KR101587859B1 (ko) * 2013-09-11 2016-01-25 한국기초과학지원연구원 폐렴연쇄상구균의 NagA 단백질을 포함하는 폐렴연쇄상구균의 감염 진단용 조성물
RU2737638C2 (ru) * 2013-12-03 2020-12-01 Вирометикс Аг ПРОЛИН-БОГАТЫЕ ПЕПТИДЫ, ЗАЩИЩАЮЩИЕ ОТ S.pneumoniae
CN106822885B (zh) 2017-02-16 2020-06-30 清华大学 肺炎链球菌疫苗
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
RU2701733C1 (ru) * 2018-12-14 2019-10-01 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU5194598A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. (streptococcus pneumoniae) antigens and vaccines
WO1998050555A2 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1998059071A1 (en) 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Lyme disease vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7129340B1 (en) 1997-07-02 2006-10-31 sanofi pasteur limited/sanofi pasteur limitée Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US5882885A (en) 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
GB9816337D0 (en) * 1998-07-27 1998-09-23 Cortecs Uk Ltd Proteins
EP1144640A3 (en) 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
DE69938670D1 (de) * 1998-12-23 2008-06-19 Id Biomedical Corp Streptococcus antigene
ES2360296T3 (es) 1999-06-10 2011-06-02 Medimmune, Llc Vacunas y proteínas de setreptococcus pneumoniae.
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
NZ519669A (en) 1999-12-23 2004-03-26 Vmax Ltd Streptococcus pyogenes virulence genes and proteins and their use
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
MXPA03009415A (es) 2001-04-16 2004-01-29 Wyeth Corp ESTRUCTURAS NOVEDOSAS DE LECTURA ABIERTA DE STREPTOCOCCUS PNEUMONIAE QUE CODIFICAN ANTIGENOS DE POLIPePTIDOS Y USOS DE LAS MISMAS.
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003242955B2 (en) 2002-04-02 2009-04-09 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US20090252756A1 (en) 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
US20070053924A1 (en) 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
AU2003268353A1 (en) 2002-08-30 2004-03-19 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
EP1545468A4 (en) 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
AU2004230244B2 (en) 2003-04-15 2011-09-22 Intercell Ag S. pneumoniae antigens
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
JP2008525033A (ja) 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
KR20070122458A (ko) 2005-02-11 2007-12-31 에이스 바이오사이언시즈 에이/에스 표재성 스트렙토코커스 뉴모니아 폴리펩티드
WO2007106407A2 (en) 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of streptococcus pneumoniae
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
WO2009011971A2 (en) 2007-05-18 2009-01-22 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health And Human Services, Centers For Disease Control And Prevention Primers and probes for the detection of streptococcus pneumoniae
EP2167531B1 (en) 2007-05-25 2012-03-21 Novartis AG Streptococcus pneumoniae pilus antigens
WO2008150885A1 (en) 2007-05-29 2008-12-11 Board Of Regents, The University Of Texas System Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2225265A2 (en) 2007-09-14 2010-09-08 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US7833776B2 (en) 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EA201591888A1 (ru) 2008-03-14 2016-05-31 Санофи Пастер Байолоджикс Ко. Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
ES2845203T3 (es) 2008-07-01 2021-07-26 Genocea Biosciences Inc Sistema de análisis de antígenos
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
WO2010150242A2 (en) 2009-06-25 2010-12-29 Protea Vaccine Technologies Ltd. Immunogenic streptococcus pneumoniae peptides and peptide-multimers
WO2011008548A1 (en) * 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (ja) 2010-04-06 2012-10-31 株式会社日立製作所 管理方法及び管理装置
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2011141968A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae

Also Published As

Publication number Publication date
KR20140017554A (ko) 2014-02-11
WO2012100233A1 (en) 2012-07-26
RU2623174C2 (ru) 2017-06-22
CN105833260A (zh) 2016-08-10
MY163871A (en) 2017-10-31
AU2012207089A1 (en) 2013-05-02
MX344120B (es) 2016-12-06
EP2665490A4 (en) 2015-07-01
EP2665490A1 (en) 2013-11-27
CA2861313A1 (en) 2012-07-26
MX2013008358A (es) 2013-09-02
AU2012207088A1 (en) 2013-05-02
NZ614460A (en) 2015-08-28
CN103501809B (zh) 2018-08-10
US20170157234A1 (en) 2017-06-08
US9393294B2 (en) 2016-07-19
CN103501809A (zh) 2014-01-08
WO2012100234A1 (en) 2012-07-26
IL227554A0 (en) 2013-09-30
US20120189649A1 (en) 2012-07-26
JP2014503002A (ja) 2014-02-06
SG192060A1 (en) 2013-08-30
JP6126993B2 (ja) 2017-05-10
EP2665490B1 (en) 2020-03-04
RU2013138563A (ru) 2015-02-27
US10188717B2 (en) 2019-01-29
SG10201600435UA (en) 2016-02-26
IL227554A (en) 2016-10-31
AU2012207089B2 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
AU2010273708A8 (en) Vaccines and compositions against Streptococcus pneumoniae
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112015008417A2 (pt) composição imunogênica, e, vacina
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112013003772A2 (pt) composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
BR112013004236A2 (pt) formulações estáveis de antígenos de neisseria meningitidis rlp2086
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
BR112016000210A2 (pt) Vacinas sintéticas contra streptococcus pneumoniae tipo 1
BR112018012310A2 (pt) sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
WO2011084967A3 (en) Methods and compositions for providing protective immunity in the elderly
BR112015028025A2 (pt) composição farmacêutica adaptada para administração oral e regime de tratamento para o controle de insuficiência adrenal
WO2013109995A3 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
BR112012029218A2 (pt) copolímeros de polissiloxano em blocos e seu uso em formulações cosméticas
BR112015021781A2 (pt) alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes
BR112014019486A8 (pt) Uso de um oligossacarídeo não digerível como um suplemento materno

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/434,818 DE 20/01/2011 POR NAO CUMPRIMENTO DE EXIGENCIA REFERENTE A COMPROVACAO DE DIREITO DE PRIORIDADE.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements